Page 4 - Mark Mintun News Today

New research shows another experimental Alzheimers drug can modestly slow patients inevitable worsening

Drugmaker has completed its FDA submission for approval of donanemab, with regulatory action expected by the end of this year

BioPharma

Donanemab significantly slowed cognitive and functional decline for amyloid-positive early symptomatic Alzheimers disease patients, lowering their risk of...

A new drug has been hailed as a "turning point in the fight against Alzheimers" after it was found to slow the progression of the…

Donanemab was found to slow "clinical decline" by up to 35%, allowing people with the disease to continue performing day-to-day tasks such as shopping, housekeeping, managing their finances and taking medication.

The health spending watchdog in England is already assessing whether the drug can be used in the NHS.

A new drug has been hailed as a “turning point in the fight against Alzheimer’s” after it was found to slow the progression of the disease.

Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimers treatment convincingly shown to delay the mind-robbing disease.

Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.